Almirall, S.A. operates as a skin health-focused biopharmaceutical company.
The company engages in the purchase, manufacture, storage, marketing, and mediation in the sale of pharmaceutical specialities and products, as well as of all types of raw m…
Analysis
Middle-of-the-road
Almirall, S.A. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.
On valuation, the picture is fair. The owner-earnings multiple stands at 18.7×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around 5% a year, against analyst forecasts of 50%. The price, in other words, assumes less than the experts do.
Growth is solid; the safety picture is adequate. The company scores 14/20 on our value-creation score: strong value creator. Analyst sentiment is cautious.
No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.
360° rank · history
1007550250
Jan 202372
85
2023202420252026
All-time high
94
Oct 2025
All-time low
48
Dec 2024
Average rank
74
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
77
67
69
83
Price/Earnings
15
32
22
37
Price/Book
75
80
88
83
Dividend Yield
61
56
61
51
Value (overall)
59
62
84
61
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.